Hello, Guest!
  • Friday, April 26, 2024

AstraZeneca Secures $287M Army Contract for COVID-19 Vaccine Delivery

AstraZeneca will supply 200 doses of the coronavirus vaccine candidate AZD1222 to the U.S. Army under a $286.9M firm-fixed-price contract.

The military branch received one bid for the procurement effort and obligated the full value of the award, the Department of Defense said Thursday.

Contract work will take place in Albuquerque, New Mexico, and West Chester Township, Ohio, through June 30, 2021.

The University of Oxford in England co-invented AZD1222 with Vaccitech, a biotechnology company that was spun out of the university's Jenner Institute.

AstraZeneca said Oct. 23 it resumed late-stage clinical trials of the experimental vaccine in the U.S.after the Food and Drug Administration completed a review of drug safety data.

Video of the Day

Related Articles

HHS, DoD Sign $486M Deal for AstraZeneca COVID-19 Drug Contract Awards

HHS, DoD Sign $486M Deal for AstraZeneca COVID-19 Drug

AstraZeneca has secured a $486M contract from the departments of Health and Human Services and Defense to further develop and test a pair of monoclonal antibodies as potential COVID-19 treatment. The company will use the funds to conduct large-scale production and Phase 3 trials of the experimental AZD7442 combo drug to help prevent or treat SARS-CoV-2 infections, HHS said Friday.

HHS, AstraZeneca Partner to Accelerate COVID-19 Vaccine Dev’t; Alex Azar Quoted News

HHS, AstraZeneca Partner to Accelerate COVID-19 Vaccine Dev’t; Alex Azar Quoted

AstraZeneca and the Department of Health and Human Services have signed a potential $1.2B public-private partnership agreement to further develop a recombinant adenovirus vaccine as potential treatment for the novel coronavirus.

Health Agencies, Biopharmaceutical Firms Form Partnership to Accelerate COVID-19 Vaccine Development News

Health Agencies, Biopharmaceutical Firms Form Partnership to Accelerate COVID-19 Vaccine Development

The National Institutes of Health and three other U.S. health agencies have teamed up with the Foundation for the NIH, European Medicines Agency and 16 biopharmaceutical companies to speed up the development of vaccines and treatments for COVID-19. The Accelerating COVID-19 Therapeutic Interventions and Vaccines partnership will work to streamline clinical trials, coordinate regulatory processes and use assets to accelerate response to the coronavirus pandemic and other future health emergencies, NIH said Friday.